Companies /Healthcare

Penumbra Inc

NYSE: PEN Medical Devices
$321.85
▲ $2.64 (+0.83%) today
Markets closed · 3:00am ET

24/7 Wall St. View

Price Prediction $338.61 +6.1% Our analysts’ 12-month view: target, optimistic case, and floor. PEN price prediction →

PEN at a Glance

Valuation
Market cap
$12.6B
P/E ratio
80.4
Profitability
Revenue (TTM)
$1.6B
Profit margin
10.1%
EPS (TTM)
$3.97
Price
52-week range
$271 – $362
24/7 target
$338.61
Street target
$362.54

Headquartered in Alameda, CA Fiscal year ends December NYSE: PEN penumbrainc.com

About Penumbra

Penumbra, Inc. is a medical device company focused on thrombectomy, the mechanical removal of blood clots throughout the body. It develops technologies for conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism) and acute limb ischemia. Its portfolio includes computer assisted vacuum thrombectomy (CAVT) systems for head-to-toe clot removal. The company reports revenue in two product categories: Thrombectomy, which covers venous, arterial and neuro clot-removal devices, and Embolization and Access, which covers embolization coils and access catheters. It sells to healthcare providers, hospitals and clinics in more than 100 countries, with the United States generating the large majority of revenue. Penumbra is the subject of a pending acquisition by Boston Scientific Corporation. As a result, it has suspended financial guidance and earnings conference calls. Updated

PEN Coverage

Frequently Asked Questions

What does Penumbra do?

Penumbra, Inc. is a medical device company focused on thrombectomy, the mechanical removal of blood clots throughout the body. It develops technologies for conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism) and acute limb ischemia.

What is the PEN stock price target?

24/7 Wall St.'s 12-month price target for PEN is $338.61, rated Buy. The Wall Street consensus target is $362.54. PEN price prediction →